- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Baicalin - ...
MedChemExpress - Model Baicalin - 21967-41-9
Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB[1][2][3].MCE products for research use only. We do not sell to patients.
Baicalin
MCE China:Baicalin
Brand:MedChemExpress (MCE)
Cat. No.HY-N0197
CAS:21967-41-9
Synonyms:Baicalein 7-O-β-D-glucuronide
Purity:98.92%
Storage:Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Shipping:Room temperature in continental US; may vary elsewhere.
Description:Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB.
In Vitro:Baicalin protects against ischemia-reperfusion injury (IRI) by altering the production of various mediators, including reactive oxygen species (ROS), Toll-like receptor (TLR)2 and TLR4, NF-κB, Bax, and Bcl-2. Baicalin treatment inhibits the increased expression of the proinflammatory cytokines TLR2/4, MyD88, p-NF-κB, and p- IκB, as well as increase the expression of IκB protein, an NF-κB inhibitor[1].Cell viability is determined by MTT assay. Compared with control cells, cell viability is significantly decreased in SH-SY5Y cells treated with thrombin. Pre-treatment with Baicalin (5, 10, 20 μM) increases cell viability in a dose-dependent manner compared with cells treated thrombin alone[2].
In Vivo:Baicalin pretreatment dose-dependently protects against a loss of renal function, with the two higher doses (10 and 100 mg/kg) significantly decreasing Scr and blood urea nitrogen (BUN) concentrations. Tissue injury, as assessed using a 0-3 point scoring system, is lower for the Baicalin treated groups than for the ischemia-reperfusion (IR)+saline group. Compared with the sham group, malondialdehyde (MDA) content is only slightly up-regulated and the SOD activity is only slightly down-regulated in rats treated with 10 and 100 mg/kg Baicalin, indicating that Baicalin abrogates the increase in oxidative stress following reperfusion[1].
Animal Administration:Rats[1] Male Wistar rats weighing 200-250 g are used. Rats are randomly divided into five groups of six rats each: (i) sham group; (ii) IR+saline group; (iii) IR+Baicalin (1 mg/kg) group; (iv) IR+Baicalin (10 mg/kg) group; and (v) IR+Baicalin (100 mg/kg) group. Renal IRI is induced by clamping the left renal artery for 45 min plus a right nephrectomy. Rats are anesthetized through an intraperitoneal injection of pentobarbital sodium (40 mg/kg body weight). After a median abdominal incision, the left renal arteries are clamped for 45 min with serrefine. After clamp removal, adequate restoration of blood flow is checked before abdominal closure. The right kidney is then removed. Sham-operated animals underwent the same surgical procedure without clamping[1].
Cell Assay:SH-SY5Y cell lines are cultured in RPMI-1640 medium supplemented with 15% fetal bovine serum at 37°C in an air atmosphere containing 95% air and 5% CO2 with a saturated humidity. Upon a confluence of 60~70%, the SH-SY5Y cells are divided into: (i) control group, incubated in RPMI-1640 medium; (ii) thrombin group, which is subject to thrombin induction (40 U/L) for 6 h based on our pre-experiment; and (iii) Baicalin groups, which are treated by Baicalin (5 μM, 10 μM, or 20 μM) for 2 h before induction of thrombin. Cell viability is measured using MTT assay. Briefly, 15 μL of the MTT solution (5 mg/mL) is added to each well and incubated for 4 h at 37°C. After removing the supernatant, 80 μL DMSO are added into each well. The absorbance is measured at 492 nm using a microplate reader. All experiments are performed in triplicate[2].
IC50 & Target:NF-κB Autophagy
Hot selling product:Dacinostat | KH-4-43 | 3'-Hydroxypterostilbene | Posaconazole | GW 501516 | Gambogic Acid | Streptomycin | Gastrodin | eGFP mRNA-LNP | Bococizumab
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19. [Content Brief]
[2]. Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7. [Content Brief]
[3]. Dai J, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci U S A. 2018;115(26):E5896-E5905. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。